Sign In
Buy DMAC
$6.34
-0.170 (-2.61%)
At Close: Jul 31, 2026
After Golden Cross, DiaMedica Therapeutics, Inc. (DMAC)'s Technical Outlook is Bright
10:55am, Tuesday, 09'th Sep 2025
DiaMedica Therapeutics, Inc. (DMAC) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, DMAC's 50-day simple moving average cross
Wall Street Analysts Believe DiaMedica Therapeutics (DMAC) Could Rally 100.81%: Here's is How to Trade
06:06pm, Monday, 08'th Sep 2025
The mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to a 100.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen
DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference
08:23am, Tuesday, 02'nd Sep 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
What Makes DiaMedica Therapeutics, Inc. (DMAC) a Strong Momentum Stock: Buy Now?
01:00pm, Thursday, 28'th Aug 2025
Does DiaMedica Therapeutics, Inc. (DMAC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect?
10:56am, Tuesday, 19'th Aug 2025
The mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to an 114.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme
DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia
03:58pm, Wednesday, 13'th Aug 2025
Positive interim phase 1a data for DM199 in preeclampsia establishes proof-of-concept and supports expansion to phase 1b and fetal growth restriction studies. DM199's mechanism targets key factors in
DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call Transcript
11:36am, Wednesday, 13'th Aug 2025
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Dietrich John Pauls - President, CEO & Director Julie Krop - Chief Medical O
DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
04:15pm, Tuesday, 12'th Aug 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025
04:15pm, Tuesday, 05'th Aug 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke,
These 4 Stocks Are Seeing Huge Insider Buying
08:45am, Friday, 01'st Aug 2025
Insider buying has been slow this past month, as buy windows close as the new earnings-reporting season gets underway.
DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement
04:30pm, Wednesday, 23'rd Jul 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced positive interim results from Part 1a of the Phase 2 study of DM19
DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
08:30am, Tuesday, 24'th Jun 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke,
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025
08:30am, Thursday, 22'nd May 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke,
